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Background: RNA interference technology has shown high therapeutic potential for cancer treatment. However,
serum instability, poor tissue permeability and non-specific uptake of short interfering RNA (siRNA) limit its
administration in vivo. To overcome these limitations and improve the specificity for ovarian cancer, we developed
a targeted nanoparticle delivery system for siRNA. This system included follicle-stimulating hormone (FSH) β 33–53
peptide as a targeting moiety that specifically recognized FSH receptor (FSHR) expressed on ovarian cancer cells.
Growth regulated oncogene α (gro-α) has been reported to be involved in ovarian cancer development and
progression. Thus, siRNA targeted to gro-α was used as an antitumor drug in this delivery system.
Methods: FSH β 33–53 peptide-conjugated gro-α siRNA-loaded polyethylene glycol (PEG)-polyethylenimine (PEI)
nanoparticles (FSH33-G-NP) were prepared and characterized by gel retardation assay and transmission electron
microscopy. Particle size and zeta potential were determined. Expression of gro-α mRNA and protein was detected
by real-time quantitative RT-PCR, immunocytochemistry and enzyme-linked immunosorbent assay. The proliferation,
migration and invasion of the ovarian clear cell carcinoma cell line ES-2 were evaluated by cell counting kit-8 assay,
cell scratch assay and transwell migration assay.
Results: A siRNA sequence that is effective in silencing gro-α expression was obtained and loaded into the targeted
delivery system. Compared with gro-α siRNA-loaded nanoparticles without FSH peptide modification (G-NP),
FSH33-G-NP significantly down-regulated gro-α expression in ES-2 cells at mRNA and protein levels. Consequently,
the aggressive biological behaviors of ES-2 cells, including proliferation, migration and invasion, were suppressed
after silencing gro-α expression, and the addition of the FSH β 33–53 peptide enhanced the suppressive effects.
Conclusions: This study indicated that a FSHR-mediated delivery system could mediate the highly selective delivery
of siRNA into ovarian cancer cells and that silencing gro-α expression could be a potential choice for ovarian cancer
treatment.
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Ovarian cancer, known as a “silent killer”, is the most
fatal of all female reproductive system malignant tumors
due to the lack of effective early diagnostic methods and
because most late-stage patients do not respond to rou-
tine treatments [1]. When compared with other epithe-
lial ovarian cancers, ovarian clear cell carcinoma is more
easily resistant to conventional platinum-based chemo-
therapy and has a worse prognosis [2]. Therefore, more
effective treatment methods are urgently needed.
Short interfering RNA (siRNA) has been considered as
a useful tool to silence genes. Recently, RNA interference
(RNAi) technology has shown high therapeutic potential
for cancer treatment [3]. However, siRNA administration
in vivo is limited because of its serum instability, poor
cellular membrane permeability and non-specific uptake
[4]. Delivery systems including liposomes, nanoparticles
(NPs), chemical modification and viral vectors have been
used to overcome these limitations [5,6]. To improve the
specificity and selectivity for tumor tissue, specific ligands
including monoclonal antibodies, peptides and small mol-
ecules have often been introduced into the delivery
systems [7].
In our previous study, we showed that follicle-stimulating
hormone (FSH) β 33–53 peptide and FSH β 81–95 peptide
are able to facilitate the access of paclitaxel-loaded NPs spe-
cifically into FSH receptor (FSHR)-positive ovarian tissues.
In addition, paclitaxel NPs modified with FSH β 33–53
peptide or FSH β 81–95 peptide showed a higher antitumor
efficacy against ovarian cancer and produced fewer adverse
side effects [8,9]. FSHR-mediated targeted therapeutics
show high potential in ovarian cancer therapy because of
limited FSHR distribution in the human reproductive sys-
tem. To specifically deliver genetic drugs including siRNA
into ovarian cancer tissues, we recently developed a
novel gene delivery system, polyethylene glycol (PEG)-
polyethylenimine (PEI) complex modified with FSH β
33–53 peptide, to deliver siRNA carried by NPs into
FSHR-positive cells [10].
Growth regulated oncogene α (gro-α), also called che-
mokine (C-X-C motif ) ligand 1, is secreted by macro-
phage, neutrophil and epithelial cells, and gro-α plays a
role in angiogenesis, inflammation and wound healing
[11]. There is high level of gro-α expression in ulcerative
colitis, colon adenomas, colon cancer, melanoma, breast
cancer, bladder cancer and ovarian cancer [12-17]. Gro-α
overexpression could promote the proliferation, invasion
and metastasis of tumor cells [18,19]. Recent studies have
shown that tissues and sera from patients with ovarian
cancer have high levels of gro-α expression, while normal
ovarian epithelial cells and fibroblasts have lower gro-α ex-
pression [20]. High levels of gro-α in stromal cells promote
the senescence of fibroblasts and consequently cause the
malignant transformation of ovarian epithelial cells [20,21].Moreover, gro-α over expression can promote the develop-
ment and progression of ovarian cancer and the formation
of endometriosis [22]. Thus, the down-regulation of gro-α
might suppress the aggressive biological behaviors of ovar-
ian cancer cells.
In this study, to overcome the limitations of siRNA ad-
ministration in vivo and improve the specificity for ovarian
cancer, we prepared FSH β 33–53 peptide-conjugated gro-
α siRNA-loaded nanoparticle. FSH β 33–53 peptide was
used as an ovarian cancer targeting moiety, and siRNA tar-
geted to gro-α was used as a therapeutic drug. The specific
down-regulation of gro-α and the suppression of aggressive
biological behaviors of ovarian clear cell carcinoma cells
were further evaluated after treatment.
Methods
Materials
FSH β 33–53 peptide (YTRDLVYKDPARPKIQKTCTF)
was synthesized by China Peptides Co., Ltd. (Shanghai,
China). Branched PEI (MW 25,000 Da) was purchased
from Sigma Aldrich Co. (St. Louis, USA). Maleimide-
conjugated PEG (Mal-PEG) was purchased from Nektar
Therapeutics (San Carlos, CA). The siSTABLE siRNA se-
quences targeted to gro-α mRNA and negative control
siRNA (siRNA-NC) were synthesized by Thermo Fisher
Scientific (Shanghai, China). The sequences were as follows:
5′-GCUGGCGGAUCCAAGCAAA-3′ (siRNA-1), 5′-TTT
CCGCCCATTCTTGAGTGT-3′ (siRNA-2), 5′-CAAGCT
TTCCGCCCATTCTTG-3′ (siRNA-3) and 5′-TATAATA
GGACAGTGTGCAGG-3′ (siRNA-4). The siRNA expres-
sion plasmid, pcDNA™6.2-GW/EmGFP-miR (5,699 bp),
was obtained from Invitrogen Trading Co., Ltd. (Shanghai,
China). DharmaFECT transfection reagent was obtained
from Thermo Fisher Scientific (Shanghai, China). FSHR
antibody and gro-α antibody were purchased from Abcam
Ltd. (San Francisco, USA). The gro-α ELISA kit was pur-
chased from R&D Systems Inc. (Minneapolis, USA). The
cDNA synthesis kit was purchased from Fermentas Inc.
(Canada). The Cell Counting Kit-8 (CCK-8) was purchased
from Dojindo Laboratories (Kumamoto, Japan).
Cell culture
The human serous ovarian carcinoma cell line SKOV-3
and human ovarian clear cell carcinoma cell line ES-2
were purchased from the Cell Bank of the Chinese
Academy of Science (Shanghai, China). SKOV-3 cells
were grown in McCoy”s 5A Medium, and ES-2 cells
were grown in RPMI 1640 medium. Medium was sup-
plemented with 10% fetal bovine serum, and cells were
cultured at 37°C in a 5% CO2 environment.
To screen for an effective siRNA sequence targeting
gro-α, ES-2 cells were seeded in 24-well plates at a density
of 1 × 105 cells per well and cultured to reach 60% conflu-
ence. Then, 1.5 μg of siRNA-1, siRNA-2, siRNA-3, siRNA-
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agent were diluted and added to the corresponding wells
according to the manufacturer’s instructions. After incu-
bation for 4 h, the medium containing siRNA was re-
placed with fresh medium containing 10% fetal bovine
serum. After 24 h or 48 h, the cell lysates were collected
for reverse transcription-polymerase chain reaction (RT-
PCR), and cell supernatants were collected for enzyme-
linked immunosorbent assay (ELISA).
To detect the suppression efficiency of gro-α by nano-
particle complexes, the same procedures were performed
as above, except that the cells were incubated with
serum-free medium containing 1.5 μg of gro-α siRNA-
loaded nanoparticles without the transfection reagents.
Preparation and characterization of FSH β 33–53 peptide-
conjugated gro-α siRNA-loaded NPs
The gro-α siRNA4-loaded nanoparticle complexes with
or without FSH β 33–53 peptide modification were pre-
pared as previously described [10]. Briefly, the solutions
containing FSH β 33–53 peptide and Mal-PEG were mixed
and magnetically stirred for 6 h at room temperature.
Then, 46.5 mg of this product, FSH33-PEG, was added to
10 mL of 2 mg/mL PEI solution and magnetically stirred
for 24 h at room temperature. The product, FSH33-PEG-
PEI, was dissolved and added into the same volume of
plasmid DNA (pDNA) (containing gro-α siRNA4) solution
drop by drop with magnetically stirring. The molar ratio of
nitrogen from PEI to phosphate from pDNA (N/P) was 25.
The final complex, FSH33-PEG-PEI-pDNA, was freeze-
dried. The PEG-PEI-pDNA complex without FSH peptide
was prepared by the same method.
The encapsulating efficiencies of the complexes were
determined by gel retardation assay. The morphologies
of the complexes were examined using the Joel Jem
2100 F transmission electron microscope (JEOL Ltd.,
Japan). Particle size and zeta potential were determined
using the Malvern Zetasizer autosize 4700 (Malvern In-
struments Ltd., Malvern, UK).
Immunocytochemistry
To detect the expression of FSHR and gro-α, immuno-
cytochemistry was used. After fixation with 4% parafor-
maldehyde, cells were incubated with FSHR antibody
(1:500) or gro-α antibody (1:500) overnight, and then in-
cubated with peroxidase-conjugated anti-rabbit IgG for
30 min. The staining reaction was performed with di-
aminobenzidine. The cells were counter-stained with
hematoxylin to detect nuclei, and imaged by light mi-
croscopy (Olympus, Tokyo, Japan).
Reverse transcription-polymerase chain reaction
RNA was isolated from cells, and 1 μg of total RNA was
reverse-transcribed using a cDNA synthesis kit accordingto the manufacturer’s instructions. The primers for detect-
ing the gro-α gene were 5′-AAGAATGGGCGGAAAGC-
3′ (forward) and 5′-CTCCTAAGCGATGCTCAAAC-3′
(reverse). The primers for the β-actin gene (ACTB) were
5′-TCCTTCCTGGGCATGGAGT-3′ (forward) and 5′-C
AGGAGGAGCAATGATCTTGAT-3′ (reverse). PCR was
performed as follows: 35 cycles consisting of denaturing at
95°C for 30 s, annealing at 55°C for 30 s, and extension at
72°C for 30 s with an initial denaturation of 5 min at 95°C
and final extension of 5 min at 72°C. The PCR products
were separated on a 1% agarose gel and analyzed using a
UV imaging system.
For real-time quantitative RT-PCR (qRT-PCR), gro-α
mRNA levels were determined with SYBR Green detec-
tion in a two-step reaction using the Eppendorf Mastercy-
cler ep Realplex RT-PCR system (Eppendorf, Hamburg,
Germany) as described previously [10]. Relative expression
levels were calculated using the 2−ΔΔCT method and were
normalized to untreated control.
Enzyme-linked immunosorbent assay
To investigate the gro-α levels secreted by cells, cell su-
pernatants were collected after treatment and examined
using a gro-α ELISA kit according to the manufacturer’s
instructions. Briefly, samples and standards were added
to ELISA microplates and incubated for 1.5 h at room
temperature. After washing, samples were incubated with
gro-α conjugate for 1 h at 4°C, and then with substrate so-
lution for 15 min at room temperature. The reaction was
stopped using stop solution. The optical density (OD) of
final products was measured using a microplate reader
(Thermo Fisher Scientific, Shanghai, China) at 450 nm
wavelength.
Cell proliferation analysis
Cells were seeded into 96-well plates at a density of 1 ×
104 cells per well and incubated overnight. Cells were in-
cubated with serum-free medium containing 1.5 μg of
gro-α siRNA-NP or FSH33-gro-α siRNA-NP for 4 h.
Medium was then replaced with fresh medium containing
10% fetal bovine serum. At 24 h, 48 h, 72 h and 96 h,
10 μl of CCK-8 solution was added and the cells incubated
for 1 h. The OD values were measured using a microplate
reader at 450 nm wavelength. The inhibition rate was cal-
culated relative to untreated cells.
Cell migration assay
To study the effects of gro-α siRNA-loaded NPs on cell
migration, a cell scratch assay was used. Cells in 24-well
plates were treated as described above. After 72 h, the
confluent cell monolayer was scraped with a 10 μl pip-
ette tip. The cells were washed twice with medium and
then cultured with serum-free medium. The cells were
examined and photographed under light microscopy at
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side of a scratch and the other were measured to evalu-
ate cell migration ability.
Cell invasion assay
A transwell migration assay was used to determine the
effects of gro-α siRNA-loaded NPs on cell invasion. Cells
in 24-well plates were treated as described above. After
24 h, cells were harvested and seeded into the upper
chambers of transwell plates pre-coated with matrigel at
a density of 1 × 104 cells per well. After incubation for
24 h, cells were fixed by submerging the chambers in 4%
paraformaldehyde for 30 min, and then stained with
hematoxylin for 15 min. A cell count of migrated cells
was determined by examining the chambers under light
microscopy.
Statistical analysis
Statistical analyses were performed using Student’s t test
by SPSS software. The data were expressed as the mean ±
SD, and a P < 0.05 was considered significant.Figure 1 Expression of FSHR and gro-α in human ovarian cancer cell
by immunocytochemistry. 1, 2 and 3, ES-2 cells stained with FSHR antibody
stained with FSHR antibody, gro-α antibody and control IgG, respectively. B
marker; lanes 1 and 2, gro-α mRNA expression in ES-2 and SKOV-3 cells, res
cells, respectively (208 bp).Results
Expression of FSHR and gro-α
To evaluate the possibility of using FSHR and gro-α as
therapeutic targets, we examined FSHR and gro-α expres-
sion in two human ovarian cancer cell lines. ES-2 cells
expressed FSHR, whereas SKOV-3 cells showed negative
expression. Both cell lines expressed gro-α at protein and
mRNA levels (Figure 1). To study targeted therapeutics in
ovarian clear cell carcinoma, the human ovarian clear cell
carcinoma cell line ES-2, which expressed both FSHR and
gro-α, was used in this study.
Screening of siRNA sequences targeted to gro-α
To determine which siRNA sequence was most effective
in silencing gro-α expression, four siRNA sequences tar-
geting gro-α mRNA were synthesized. The levels of gro-
α mRNA and protein in ES-2 cells were quantified by
real-time qRT-PCR and ELISA methods 24 h or 48 h after
treatment with different siRNA sequences and Dharma-
FECT transfection reagent. As shown in Figure 2A, gro-α
mRNA was down-regulated to 82.1%, 88.2%, 64.5% andlines SKOV-3 and ES-2. (A) Detection of FSHR and gro-α expression
, gro-α antibody and control IgG, respectively; 4, 5 and 6, SKOV-3 cells
ar, 20 μm. (B) Detection of gro-α mRNA expression by RT-PCR. M, DNA
pectively (226 bp); lanes 3 and 4, ACTB expression in ES-2 and SKOV-3
Figure 2 Expression of gro-α mRNA and protein after treatment
with siRNA targeted to gro-α. (A) Detection of gro-α mRNA ex-
pression by qRT-PCR. (B) Detection of gro-α protein expression in
cell supernatants by ELISA. ES-2 cells were treated with one of four
siRNA sequences along with DharmaFECT transfection reagent for
4 h. Gro-α mRNA and gro-α protein secreted in cell supernatants
were quantified 24 h or 48 h after treatment.
Figure 3 Characterization of nanoparticle complexes. (A)
Transmission electron micrographs. 1, FSH33-G-NP; 2, G-NP. Bar,
500 nm. (B) The encapsulating efficiency as determined by gel re-
tardation assay. Lane 1, naked pDNA; lanes 2 to 8, FSH33-G-NP at
the N/P ratios of 1, 5, 10, 15, 20, 25 and 30, respectively; lanes 9 to
15, G-NP at the N/P ratios of 1, 5, 10, 15, 20, 25 and 30, respectively.
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and siRNA4, respectively. Consequently, gro-α protein
secreted in supernatants was reduced to 84.4%, 91.0%,
66.1% and 48.7% of the control level by siRNA1,
siRNA2, siRNA3 and siRNA4, respectively (Figure 2B).
Thus, siRNA4 was used as the targeted sequence to sup-
press gro-α expression in this study.
Characterization of FSH β 33–53 peptide-conjugated gro-
α siRNA-loaded NPs
To prepare FSH β 33–53 peptide-conjugated gro-α siRNA-
loaded NPs, gro-α siRNA4 was encoded into a linear
mammalian siRNA expression plasmid, pcDNATM6.2-
GW/EmGFP-miR. The complexes of gro-α siRNA-loaded
NPs (G-NP) and FSH β 33–53 peptide-conjugated gro-α
siRNA-loaded NPs (FSH33-G-NP) were then prepared
as previously described [10]. The transmission electronmicrographs of the complexes are shown in Figure 3A.
Gro-α siRNA-loaded NPs modified with or without FSH
β 33–53 peptide exhibited spherical shapes, with aver-
age diameters of 143.4 ± 13.2 nm and 129.2 ± 5.0 nm,
respectively. The average zeta potential values were
39.8 ± 1.1 mV and 37.4 ± 2.8 mV, respectively. As shown
in Figure 3B, the plasmid DNA containing gro-α siRNA
was completely retarded when N/P ratios were greater
than 10, which indicated an encapsulation efficiency
value of 100%.
Down-regulation of gro-α expression by FSH β 33–53
peptide-conjugated gro-α siRNA-loaded NPs
We previously reported that FSH33-G-NP with an N/P
ratio of 25 has a higher transfection efficiency than the
complex without FSH β 33–53 peptide modification,
and a higher gro-α inhibition rate (39%, down-regulated
to 61% of the control level) in ES-2 cells treated with
targeted complexes containing gro-α siRNA for 48 h
[10]. In this study, we further investigated the suppression
efficiency of gro-α expression by different complexes.
Gro-α mRNA and protein levels in ES-2 cells were quanti-
fied by qRT-PCR and ELISA methods 24 h or 48 h after
treatment with different complexes containing 1.5 μg of
plasmid DNA. As shown in Figure 4A, gro-α mRNA was
down-regulated to 79.3% and 40.9% of the control level at
24 h after treatment with G-NP and FSH33-G-NP, re-
spectively. Consequently, levels of gro-α protein secreted
Figure 4 Expression of gro-α mRNA and protein after treatment
with gro-α siRNA-loaded NPs. (A) Expression of gro-α mRNA as
determined by qRT-PCR. (B) Expression of gro-α protein secreted in
cell supernatants as determined by ELISA. ES-2 cells were treated
with different nanoparticle complexes for 4 h. Gro-α mRNA and gro-
α protein secreted in cell supernatants were quantified 24 h or 48 h
after treatment.
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control level at 48 h after treatment by G-NP and
FSH33-G-NP, respectively (Figure 4B). The differences
between the two NP complex-treated groups were sta-
tistically significant. These data further indicated that
the efficiency of suppressing the target gene gro-α could
be enhanced by the targeting moiety, FSH β 33–53 pep-
tide, which specifically recognizes FSHR expressed in
ES-2 cells. Moreover, the inhibition rate of FSH33-G-
NP to gro-α expression was similar to DharmaFECT
transfection reagent-mediated transfection of gro-α siRNA4
(Figure 2). However, transfection reagents such as Dharma-
FECT and lipofectamine 2000 cannot be used in vivo. The
complexes we synthesized could be uptaken by cancer cells
without the help of transfection reagents and could be used
in vivo.Suppression of aggressive biological behaviors of ES-2
cells by FSH β 33–53 peptide-conjugated gro-α
siRNA-loaded NPs
The proliferation, migration and invasion of ES-2 cells
were investigated after ES-2 cells were treated with
different complexes containing 1.5 μg of plasmid DNA
containing gro-α siRNA. As shown in Figure 5A, the
proliferation of ES-2 cells was inhibited by gro-α siRNA-
loaded NPs modified with or without FSH β 33–53 pep-
tide. Compared with control and G-NP, FSH33-G-NP
significantly inhibited ES-2 cells. The inhibition rate at
96 h was 39.1%, which was 2.8-fold higher than that seen
with G-NP. The migration ability of ES-2 cells at 36 h was
also significantly inhibited by FSH33-G-NP, with a migra-
tion distance of 1.6 mm, which was 4.7-fold lower than
that of cells treated with G-NP (Figure 5B and 5D). Simi-
larly, the number of migrated cells in the FSH33-G-NP
group was significantly reduced compared to that in the
G-NP (without FSH β 33–53 peptide conjugation) group.
The number of migrated cells in the FSH33-G-NP group
was 2.4-fold lower than that in the G-NP group (Figure 5C
and 5E). These data suggested that the aggressive bio-
logical behaviors of ES-2 cells were suppressed by gro-α
siRNA-loaded NPs. More importantly, the targeting moi-
ety, FSH β 33–53 peptide, significantly enhanced the
suppressive effects.
Discussion
To find an effective targeted therapy strategy for ovarian
cancer and a stable delivery system for siRNA, we devel-
oped an active targeted gene delivery system mediated
by FSHR and showed its promising effects for down-
regulating the target gene and suppressing ovarian can-
cer cells.
Our group previously reported that an active targeted
nanoparticle drug delivery system mediated by FSHR
has a high selectivity for FSHR-positive ovarian cancer
cells, and that the nanoparticles modified with FSH β
33–53 or β 81–95 peptide deliver more chemotherapeu-
tic drugs into ovarian cancer cells and significantly en-
hance the antitumor efficacy of chemotherapeutic drugs
[8,9,23]. Thus, FSH β 33–53 peptide was used as a tar-
geting moiety in this gene delivery system.
However, the chemotherapeutic drugs we used before,
such as paclitaxel, target ovarian cancer cells themselves
rather than the whole tumor tissue. Tumors are well-
organized tissues rather than a cluster of cancer cells.
Tumor-associated stroma plays an important role as a
niche for cancer cells and is not a passive bystander dur-
ing the process of oncogenesis [24-26]. The stroma sur-
rounding cancer epithelial cells not only provides a
supportive and nutritive microenvironment for cancer
cells, but it also assists in the development and progres-
sion of cancer [27-29]. The radiation-induced mammary
Figure 5 The proliferation, migration and invasion of ES-2 cells after treatment with gro-α siRNA-loaded NPs. (A) ES-2 cell proliferation as
determined by CCK-8 assay. Cells were incubated with serum-free medium containing G-NP or FSH33-G-NP for 4 h. At 24 h, 48 h, 72 h and 96 h,
CCK-8 solution was added, and OD values at 450 nm were measured. (B) Determination of ES-2 cell migration by scratch assay. The cell mono-
layer was scraped 72 h after treatment. Cells were then photographed under light microscopy at 12 h and 36 h after scraping. (C) Determination
of ES-2 cell invasion by transwell migration assay. 1, untreated cells; 2, cells treated with G-NP; 3, cells treated with FSH33-G-NP. Bar, 20 μm. Cells
were harvested at 24 h after treatment and seeded into the upper chambers of transwell plates pre-coated with matrigel. After 24 h, cells were
fixed, stained and examined by light microscopy. (D) Determination of cell migration distances by scratch assay at 36 h. (E) Determination of mi-
grated cell counts by transwell migration assay.
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plastic progression of non-tumorigenic mammary epithe-
lial cells [30]. Thus, the therapeutic approaches that only
aim at cancer epithelial cells could not destroy the well-
organized tumor tissue thoroughly. The remaining cancer
cells or premalignant epithelium could proliferate again
with the support of their surrounding stromal cells includ-
ing inflammatory cells, endothelial cells and fibroblasts.
In order to create a favorable microenvironment, can-
cer cells might have a cross-talk with their surrounding
stroma. Blocking the cross-talk network could suppress
the development and progression of cancer. Recent stud-
ies have reported that pro-inflammatory cytokines such
as gro-α, interleukin 6 (IL-6) and interleukin 8 (IL-8) have
the potential to modulate stroma and promote tumor
growth [20,31,32]. A model was hypothesized by Liu to
describe the inflammatory network bridging senescentstroma and tumorigenesis [33]. In this model, both initi-
ated epithelium and senescent stroma can produce some
molecules such as gro-α, IL-6 and IL-8, and then, they can
promote further tumorigenesis and senescence by para-
crine signaling. Gro-α and its receptor have been found to
be overexpressed in ovarian cancers and play critical roles
in the development and progression of ovarian cancer
[20]. Therefore, siRNA to silence gro-α was introduced
into the FSHR-mediated delivery system and its antitumor
effects were further evaluated in this study.
High levels of gro-α are essential for malignant trans-
formation of normal ovarian epithelial cells and can pro-
mote the proliferation of tumor cells [20,34]. It has been
reported that the continuous expression of gro-α, -β, or -γ
in immortalized melanocytes results in nearly 100% tumor
formation in SCID mouse models. Antibodies to gro pro-
teins are able to slow or inhibit the formation of tumors
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gro-α with RNAi technology also results in a 20% decrease
in esophageal cancer cell proliferation [36]. In our study,
the proliferation of the ovarian clear cell carcinoma cell
line ES-2 was inhibited after gro-α was silenced with gro-
α siRNA-loaded NPs. Compared with gro-α siRNA-loaded
NPs without FSH peptide modification, gro-α siRNA-
loaded NPs modified with FSH β 33–53 peptide showed
an enhanced inhibitive effect to ES-2 cells. It could be due
to the peptide fragments specifically binding to FSHR on
ovarian cancer cells, thus greatly improving cell uptake by
receptor-mediated endocytosis and internalization.
Gro-α over-expression is also involved in tumor cell
migration and invasion, and ultimately promotes cancer
metastasis [16,19,37]. Gro-α might be an independent
predictor for bladder cancer metastasis [38]. U251 gli-
oma cells transfected with gro-α express high levels of
several proteins associated with migratory behavior and
exhibit stronger motility and invasiveness. The implant-
ation of gro-α glioma clones into the brains of nude
mice form larger intracerebral tumors and cause the
early death of mice [39]. In addition, CXC chemokines
(including gro-α) that are secreted by endothelial cells
can induce tumor cell invasion, whereas the blockade of
the gro-α receptor CXCR2 can inhibit the invasion of
oral squamous cell carcinoma-3 and Kaposi’s sarcoma
cells into endothelial cells [40]. Similarly, the invasion
and migration of breast cancer cells is markedly reduced
after treatment with anti-gro antibody [41]. In colorectal
cancer liver metastases, down-regulation of gro-α results
in the inhibition of cell viability, invasion and prolifera-
tion in vitro and almost completely prevented tumor
growth in vivo [42]. We examined the migration and in-
vasion activities of ES-2 cells by cell scratch and trans-
well migration assays. The data showed that silencing
gro-α expression markedly inhibited cell migration and
invasion. Compared to gro-α siRNA-loaded NPs, the
complex modified with a targeting moiety had an en-
hanced suppressive effect on ES-2 cells, which indicated
that targeting moieties such as receptor-binding peptides
could improve the intake of siRNAs carried by NPs and
could enhance the effect of RNA interference.
Conclusions
Taken together, this study indicated that silencing gro-α
expression suppressed the proliferation, migration and
invasion of ovarian clear cell carcinoma cells and that
the FSHR-mediated nanoparticle delivery system provided
a highly efficient delivery tool for gro-α siRNA into FSHR-
expressing cells. Thus, silencing gro-α by a receptor-
mediated targeted strategy is a potential choice for ovarian
cancer treatment. However, further studies in vivo are re-
quired to investigate the therapeutic effects of this tar-
geted complex in ovarian cancer.Abbreviations
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